Su Li, Mi Ping, Niu Wenqiang, Zhou Ting, Yang Wang, Chen Cheng, Huang Chenggang
The Central Hospital of Xiaogan, Department of Nuclear Medicine, Xiaogan City, Hubei Province, China.
J Med Biochem. 2024 Nov 16;43(6):897-907. doi: 10.5937/jomb0-48734.
Thyroid-associated ophthalmopathy (TAO) is an autoimmune response to inflammation of the thyroid and orbital tissue. This research evaluated the efficacy of 99Tcm-DTPA orbital SPECT/CT combined with thyroid function test in radioactive iodine I-131 (RAI) treatment of TAO-hyperthyroidism.
We retrospectively studied clinical activity score (CAS), blood thyrotropine (TSH), free triiodothyronine (FT3), free thyroxine (FT4), thickness of extra-ocular muscle (EOM), and uptake rate (UR) of 99Tcm-DTPA orbital SPECT/CT of 43 patients after 6 months of treatment with 20 mCi RAI. Parameters were compared before and after RAI in patients assessed as effectively treated (normal thyroid function or hypothyroidism), and correlations between blood FSH, FT3, FT4, thickness of EOM, and UR were analyzed after treatment.
After RAI, 35 cases (70 eyes, 81.4%) had normal or hypothyroidism, and 8 cases (16 eyes, 18.6%) had hyperthyroidism. Compared with the patients who failed treatment, effectively treated patients had lower CAS, FT3, FT4, and UR and higher blood TSH. In patients with effective treatment, UR of the inferior rectus muscle was positively correlated with FT3 and FT4. Adverse RAI outcomes were associated with smoking and higher iodine-thyroid iodine uptake before treatment.
Combined with TSH, FT3, and FT4 levels, the reduction of 99Tcm-DTPA orbital SPECT/CT UR also indicates an improvement in the disease course of patients. The UR of the inferior rectus muscle can be an objective index to evaluate the curative effect of TAO patients.
甲状腺相关性眼病(TAO)是一种针对甲状腺和眼眶组织炎症的自身免疫反应。本研究评估了99锝-二乙三胺五乙酸(99Tcm-DTPA)眼眶单光子发射计算机断层扫描/计算机断层扫描(SPECT/CT)联合甲状腺功能检查在放射性碘I-131(RAI)治疗TAO合并甲状腺功能亢进症中的疗效。
我们回顾性研究了43例接受20毫居里RAI治疗6个月后的患者的临床活动评分(CAS)、血促甲状腺激素(TSH)、游离三碘甲状腺原氨酸(FT3)、游离甲状腺素(FT4)、眼外肌(EOM)厚度以及99Tcm-DTPA眼眶SPECT/CT的摄取率(UR)。对评估为有效治疗(甲状腺功能正常或甲状腺功能减退)的患者在RAI治疗前后的参数进行比较,并分析治疗后血促卵泡生成素(FSH)、FT3、FT4、EOM厚度和UR之间的相关性。
RAI治疗后,35例(70只眼,81.4%)甲状腺功能正常或减退,8例(16只眼,18.6%)甲状腺功能亢进。与治疗失败的患者相比,有效治疗的患者CAS、FT3、FT4和UR较低,血TSH较高。在有效治疗的患者中,下直肌的UR与FT3和FT4呈正相关。RAI治疗的不良结果与吸烟以及治疗前较高的碘-甲状腺碘摄取有关。
结合TSH、FT3和FT4水平,99Tcm-DTPA眼眶SPECT/CT UR的降低也表明患者病程有所改善。下直肌的UR可作为评估TAO患者治疗效果的客观指标。